NeuroMetrix stock soars over pain device distribution deal; Third Rock Ventures on a roll;

@FierceMedDev: Biocept Laboratories becomes latest Dx outfit to explore IPO. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Medtronic won expanded indications for one of its key vascular stents. Release | Article | Follow @MarkHFierce

> Edwards Lifesciences ($EW) priced $600 million of senior notes that will, in part, help repay debt. Item

> NeuroMetrix ($NURO) saw its stock soar late Tuesday after announcing a distribution deal with a national diabetes mail-order supply company for its new pain-management device. Story

> Labcyte will work with AstraZeneca ($AZN) to use acoustic sample handling for mass spectrometry to advance drug discovery. Item

> Oraya Therapeutics reports positive two-year safety data for its Oraya therapy, which uses low-energy, highly targeted X-rays to treat wet age-related macular degeneration. Item

> Australian researchers found that an insulin pump that automatically stopped pumping helped reduce serious hypoglycemia in patients with high-risk Type 1 diabetes. Story

> Illumina ($ILMN) is applying the CE mark toward expanded lab use of technology that facilitates the development of diagnostic tests. Item

> Nature profiles the founders of Third Rock Ventures, backers of life sciences companies including Foundation Medicine, the cancer diagnostics outfit that just went public with a $106 million IPO. Story

Biotech News

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | FierceBiotech's 2013 Fierce 15 | Follow @FierceBiotech

@JohnCFierce: Merck KGaA doubles down on Oncothyreon's failed cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Apparently no one wanted to spend ~$3B on Clovis Oncology. Perhaps Big Pharma wants its biotechs to generate revenue. Story | Follow @DamianFierce

@EmilyMFierce: Stem cell reprogramming made easier by removing one protein. Popular yesterday from FierceBiotech Research | Follow @EmilyMFierce

> Plotting Asia expansion, Amgen blueprints plans for Shanghai research center. More

> Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M. Article

Pharma News

@FiercePharma: Lundbeck's refusal to sell pentobarbital to prisons hits Ohio's execution plans. More from Reuters | Follow @FiercePharma

@EricPFierce: FDA warning letter for Strides Arcolab Agila Specialties plant arrives. Mylan not too concerned. Story from FiercePharmaManufacturing | Follow @EricPFierce

> Cost gatekeepers give final 'no' to Pfizer's targeted cancer drug Xalkori. Report

> Eli Lilly's diabetes strategy doesn't include big staff-up in sales. Article

Drug Delivery News

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. Story | Follow @MichaelGFierce

> Study: Artificial pancreas with inhaled insulin improves glucose control. More

> Alnylam heralds positive results for RNAi amyloidosis drug. Article

> Surefire collects $16.4M to expand cancer-drug catheter biz. Item

> Bind collects $70.5M IPO to support Accurin tech. Story

Diagnostics News

> Cognoptix Alzheimer's eye test generates robust trial results. Article

> Alzheimer's diagnosis may gain from PET imaging of tau proteins. Report

> Case Western, GSK find promise with MS diagnostic 'probe.' Story

> In vitro Dx to remain at top of med tech heap. More

> Cigna: Genetic counseling mandates will come for other Dx tests. Article

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.